To determine whether Rac and Cdc42 inhibitors affect leukocyte migration in vivo, we quantified leukocytes by immunofluorescence or flow cytometry in tumors or spleen in preclinical breast cancer mouse models. This evidence concerns the gene AKT1 and breast carcinoma.